This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Divine Skin Announces New Pain Reliever To Compete With Tylenol, Advil, Aspirin

Stocks in this article: DSKX

MIAMI BEACH, Fla., June 13, 2011 /PRNewswire/ -- Today Divine Skin Inc. (DSKX), a developer of personal-care biotechnology, announced plans to release a new oral analgesic intended to compete over the counter with the likes of Tylenol, Advil, and aspirin. The company plans to begin shipping upon final authorization by the Drug Enforcement Administration.

"Since Divine Skin focuses on underserved and niche categories, of course our pain medication will offer patients some benefits that competitors don't. The product will give better pain relief, with a safety profile similar to that of Advil," explained Daniel Khesin, chairman and CEO.

"We certainly don't expect to take significant market share away from the huge players, since consumers have been taking Tylenol and Advil for generations. Instead, we will target an audience that appreciates more advanced biotechnology. If we win just one tenth of one percent of the market — which we will — then we'll be happy," he said.

In the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, antiarthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4 billion in 2009, according to an August 2010 report published by the US Census Bureau.

Each patient responds differently to each type of pain and pain reliever. A few years ago, Khesin himself endured a grueling experience with chronic pain after suffering a catastrophic spinal cord injury, which put him in a wheelchair for months. During his recovery, he tried nearly all of the pain relievers then available, including some strong narcotics.

That ordeal, combined with his expertise in business development and the commercialization of new biotechnologies, resulted in what he believed might become a unique over-the-counter medication. Laboratory research showed promise for the new formula, and subsequent clinical studies confirmed the drug's effectiveness.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs